CHAPTER 1 INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2 RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1. Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3 MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4 MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Rising focus on preventive healthcare
4.1.2. Need to control healthcare costs
4.1.3. A significant increase in venture capital investments
4.1.4. Increasing incidence of preventable chronic diseases
4.2. Market Restraints & Challenges
4.2.1. Patient data privacy concerns
4.2.2. Unfavourable payment models
4.3. Market Opportunities
4.3.1. Unexplored therapeutic applications
4.3.2. Emerging markets offer significant growth opportunities
CHAPTER 5 GLOBAL DIGITAL THERAPEUTICS MARKET – BY SALES CHANNEL
5.1. Introduction
5.2. B2C
5.2.1. Caregivers
5.2.2. Patients
5.3. B2B
5.3.1. Providers
5.3.2. Payers
5.3.3. Pharmaceutical Companies
5.3.4. Employers
5.3.5. Other Buyers
CHAPTER 6 GLOBAL DIGITAL THERAPEUTICS MARKET – BY TYPE OF APPLICATION
6.1. Introduction
6.2. Preventive applications
6.2.1. Prediabetes
6.2.2. Obesity
6.3. Treatment/Care-related applications
6.3.1. Diabetes
6.3.2. Central nervous system (CNS) Disorders
6.3.3. Chronic respiratory diseases (CRD)
6.3.4. Musculoskeletal disorders
6.3.5. Cardiovascular diseases
6.3.6. Smoking cessation
6.3.7. Medication adherence
6.3.7. Other applications
CHAPTER 7 GLOBAL DIGITAL THERAPEUTICS MARKET - BY GEOGRAPHY
7.1. Introduction
7.2. North America
7.2.1. U.S.
7.2.2. Canada
7.2.3. Mexico
7.2.4. Costa Rica
7.3. South America
7.3.1. Brazil
7.3.2. Argentina
7.3.3. Chile
7.3.4. Columbia
7.3.5. Others
7.4. Europe
7.4.1. U.K.
7.4.2. Germany
7.4.3. France
7.4.4. Italy
7.4.5. Spain
7.4.6. Russia
7.4.7. Netherlands
7.4.7. Switzerland
7.4.8. Poland
7.4.9. Others
7.5. Asia Pacific
7.5.1. China
7.5.2. Japan
7.5.3. India
7.5.4. South Korea
7.5.5. Australia & New Zealand
7.5.6. Malaysia
7.5.7. Singapore
7.5.8. Others
7.6. Middle East & Africa
7.6.1. UAE
7.6.2. Saudi Arabia
7.6.3. Iran
7.6.4. Iraq
7.6.5. Qatar
7.6.6. South Africa
7.6.7. Algeria
7.6.8. Morocco
7.6.9. Nigeria
7.6.10. Egypt
7.6.11. Others
CHAPTER 8 GLOBAL DIGITAL THERAPEUTICS MARKET - COMPANY PROFILES
8.1. Canary Health, Inc.
8.2. IBM Corporation
8.3. Evolent Health, Inc.
8.4. Livongo Health, Inc.
8.5. Mango Health, Inc.
8.6. Nanobiosym, Inc.
8.7. Noom Health, Inc.
8.8. Omada Health, Inc.
8.9. Pear Therapeutics, Inc.
8.10. Perfint Healthcare Pvt. Ltd.
8.11. Reciprocal Labs Corporation.
8.12. Proteus Digital Health.
8.13. Twine Health, Inc.
8.14. Well Doc Inc.
8.15. Zest Health, LLC.
CHAPTER 9 GLOBAL DIGITAL THERAPEUTICS MARKET - COMPETITIVE LANDSCAPE
9.1. Market Share Analysis
9.2. Strategies adopted by top companies
9.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 10 MARKET INSIGHTS
10.1. Industry Experts Insights
10.2. Analysts Opinions
10.3. Investment Opportunities
CHAPTER 11 APPENDIX
11.1. List of Tables
11.2. List of Figures
